Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2): An Update

Mahendra Pal, Gemechu Berhanu, Chaltu Desalegn, Venkataramana Kandi, Mahendra Pal, Gemechu Berhanu, Chaltu Desalegn, Venkataramana Kandi

Abstract

Coronaviruses (CoVs) belong to the family of Coronaviridae, the order Nidovirales, and the genus Coronavirus. They are the largest group of viruses causing respiratory and gastrointestinal infections. Morphologically, CoVs are enveloped viruses containing a non-segmented positive-sense, single-stranded ribonucleic acid (RNA) viruses. CoVs are categorized into four important genera that include Alphacoronavirus, Betacoronavirus, Gammacoronavirus, and Deltacoronavirus. A novel member of human CoV that has recently emerged in Wuhan, China, is now formally named as SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2). This is a unique strain of RNA viruses that have not been previously observed in humans. The virus has wide host adaptability and is capable of causing severe diseases in humans, masked palm civets, mice, dogs, cats, camels, pigs, chickens, and bats. The SARS-CoV-2 typically causes respiratory and gastrointestinal sickness in both humans and animals. It can be transmitted through aerosols and direct/indirect contact, as well as during medical cases and laboratory sample handling. Specific structural proteins, which might be found on the surface of the virus, play an important role in the pathogenesis and development of the complications. The disease is characterized by distinct medical signs and symptoms that include high fever, chills, cough, and shortness of breath or difficulty in breathing. The infected people may also present with other symptoms such as diarrhea, myalgia, fatigue, expectoration, and hemoptysis. It is important from the public health and economic point of view as it affects the growth of the country, which is majorly attributed to the restriction in the movement of the people and the cost associated with the control and prevention of the disease. Since there is no specific therapeutic intervention nor a vaccine available against the virus, supportive management and treatment with non-specific therapeutic agents (repurposed drugs) may provide relief to the patients. Some preventive strategies of the disease include blocking the routes of transmission of the infections, disinfection of instruments used during medical case handling, using personal protective equipment, proper and early diagnosis of the disease, avoiding contact with the sick patients, and quarantine of the infected/exposed people.

Keywords: aerosols; bats; beta coronavirus; coronavirus; humans and animals; public health; quarantine; respiratory and gastrointestinal infections; sars-cov-2; severe acute respiratory syndrome coronavirus-2.

Conflict of interest statement

The authors have declared that no competing interests exist.

Copyright © 2020, Pal et al.

Figures

Figure 1. The classification of the RNA…
Figure 1. The classification of the RNA group of viruses and the origin of SARS CoV-2
CoV: coronavirus; SARS CoV 2: severe acute respiratory syndrome coronavirus 2; MERS CoV, Middle East respiratory syndrome coronavirus; RNA, ribonucleic acid

References

    1. Coronavirus infections-more than just the common cold. Paules CI, Marston HD, Fauci AS. JAMA. 2020;323:707–708.
    1. A novel coronavirus associated with severe acute respiratory syndrome. Ksiazek TG, Erdman D, Goldsmith CS, et al. N Engl J Med. 2003;348:1953–1966.
    1. ECDC technical report: Interim guidance for environmental cleaning in non-healthcare facilities exposed to SARS-CoV-2. [Mar;2020 ]; 2020
    1. 2019 novel coronavirus (COVID-19) outbreak: a review of the current literature. Sahin AR, Erdogan A, Agaoglu PM, et al. EJMO. 2020;4:1–7.
    1. Coronaviruses: an overview of their replication and pathogenesis. Fehr AR, Perlman S. Methods Mol Biol. 2015;1282:1–23.
    1. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Huang C, Wang Y, Li X, et al. Lancet. 2020;395:497–506.
    1. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. Wang D, Hu B, Hu C, et al. JAMA. 2020;323:1061–1069.
    1. Cumulative number of reported probable cases of SARS. [Mar;2020 ]; 2003
    1. Coronavirus pathogenesis. Weiss SR, Leibowitz JL. Adv Virus Res. 2011;81:85–164.
    1. Severe acute respiratory syndrome: a newly recognized viral zoonosis of public health concern. Pal M. Acta Scientific Microbiology. 2018;1:1.
    1. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lu R, Zhao X, Li J, et al. Lancet. 2020;395:565–574.
    1. Coronavirus disease (COVID-19) pandemic. [Mar;2020 ]; 2020
    1. Clinical findings in a group of patients infected with the 2019 novel coronavirus (SARS-Cov-2) outside of Wuhan, China: retrospective case series. Xu XW, Wu XX, Jiang XG, et al. BMJ. 2020;368:0.
    1. Emerging coronaviruses: genome structure, replication, and pathogenesis. Chen Y, Liu Q, Guo D. J Med Virol. 2020;92:418–423.
    1. Situation summary. [Mar;2020 ]; 2020
    1. Three emerging coronaviruses in two decades: the story of SARS, MERS, and now COVID-19. Guarner J. Am J Clin Pathol. 2020;153:420–421.
    1. Structure, function, and evolution of coronavirus spike proteins. Li F. Annu Rev Virol. 2016;3:237–261.
    1. Potential maternal and infant outcomes from (Wuhan) coronavirus 2019-nCoV infecting pregnant women: lessons from SARS, MERS, and other human coronavirus infections. [Mar;2020 ];Schwartz DA, Graham AL. Viruses. 2020 12:0.
    1. A novel coronavirus from patients with pneumonia in China, 2019. Zhu N, Zhang D, Wang W, et al. N Engl J Med. 2020;382:727–733.
    1. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Zhou P, Yang XL, Wang XG, et al. Nature. 2020;579:270–273.
    1. T cell responses are required for protection from clinical disease and for virus clearance in severe acute respiratory syndrome coronavirus-infected mice. Zhao J, Zhao J, Perlman S. J Virol. 2010;84:9318–9325.
    1. Supramolecular architecture of severe acute respiratory syndrome coronavirus revealed by electron cryomicroscopy. Neuman BW, Adair BD, Yoshioka C, et al. J Virol. 2006;80:7918–7928.
    1. Cryo-electron tomography of mouse hepatitis virus: Insights into the structure of the coronavirion. Bárcena M, Oostergetel GT, Bartelink W, et al. Proc Natl Acad Sci U S A. 2009;106:582–587.
    1. COVID-19. [Mar;2020 ]; 2020
    1. SARS and MERS: recent insights into emerging coronaviruses. de Wit E, van Doremalen N, Falzarano D, Munster VJ. Nat Rev Microbiol. 2016;14:523–534.
    1. Practical recommendations for critical care and anesthesiology teams caring for novel coronavirus (2019-nCoV) patients. Wax RS, Christian MD. Can J Anaesth. 2020
    1. Origin and evolution of pathogenic coronaviruses. Cui J, Li F, Shi ZL. Nat Rev Microbiol. 2019;17:181–192.
    1. Genome composition and divergence of the novel coronavirus (2019-nCoV) originating in China. Wu A, Peng Y, Huang B, et al. Cell Host Microbe. 2020;27:325–328.
    1. The aetiology, origins, and diagnosis of severe acute respiratory syndrome. Poon LL, Guan Y, Nicholls JM, Yuen KY, Peiris JS. Lancet Infect Dis. 2004;4:663–671.
    1. Management of critically ill patients with severe acute respiratory syndrome (SARS) [Mar;2020 ];Lau AC, Yam LY, So LK. Int J Med Sci. 2004 1:1–10.
    1. The effects of temperature and relative humidity on the viability of the SARS coronavirus. Chan KH, Peiris JS, Lam SY, Poon LL, Yuen KY, Seto WH. Adv Virol. 2011;2011:734690.
    1. Stability of Middle East respiratory syndrome coronavirus (MERS-CoV) under different environmental conditions. van Doremalen N, Bushmaker T, Munster VJ. Euro Surveill. 2013;18:0.
    1. Preliminary estimation of the basic reproduction number of novel coronavirus (2019-nCoV) in China, from 2019 to 2020: A data-driven analysis in the early phase of the outbreak. Zhao S, Lin Q, Ran J, et al. Int J Infect Dis. 2020;92:214–217.
    1. The next big threat to global health? 2019 novel coronavirus (2019-nCoV): What advice can we give to travellers? - Interim recommendations January 2020, from the Latin-American society for Travel Medicine (SLAMVI) Biscayart C, Angeleri P, Lloveras S, Chaves TDSS, Schlagenhauf P, Rodríguez-Morales AJ. Travel Med Infect Dis. 2020;33:101567.
    1. Novel Wuhan (2019-nCoV) coronavirus. Carlos WG, Dela Cruz CS, Cao B, Pasnick S, Jamil S. Am J Respir Crit Care Med. 2020;201:0.
    1. A novel coronavirus emerging in China - key questions for impact assessment. Munster VJ, Koopmans M, van Doremalen N, van Riel D, de Wit E. N Engl J Med. 2020;382:692–694.
    1. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): the epidemic and the challenges. Lai CC, Shih TP, Ko WC, Tang HJ, Hsueh PR. Int J Antimicrob Agents. 2020;55:105924.
    1. Human coronaviruses: insights into environmental resistance and its influence on the development of new antiseptic strategies. [Mar;2020 ];Geller C, Varbanov M, Duval RE. Viruses. 2012 4:3044–3068.
    1. Viral shedding patterns of coronavirus in patients with probable severe acute respiratory syndrome. Cheng PK, Wong DA, Tong LK, et al. Lancet. 2004;363:1699–1700.
    1. SARS-CoV pathogenesis is regulated by a STAT1 dependent but a type I, II and III interferon receptor independent mechanism. Frieman MB, Chen J, Morrison TE, et al. PLoS Pathog. 2010;6:0.
    1. Advances in clinical diagnosis and treatment of severe acute respiratory syndrome. Nie QH, Luo XD, Hui WL. World J Gastroenterol. 2003;9:1139–1143.
    1. The economic impact of SARS in Beijing, China. Beutels P, Jia N, Zhou QY, Smith R, Cao WC, de Vlas SJ. Trop Med Int Health. 2009;14:85–91.
    1. Evaluation and validation of an enzyme-linked immunosorbent assay and an immunochromatographic test for serological diagnosis of severe acute respiratory syndrome. Guan M, Chan KH, Peiris JS. Clin Diagn Lab Immunol. 2004;11:699–703.
    1. Laboratory diagnosis of SARS. Chan PK, To WK, Ng KC, et al. Emerg Infect Dis. 2004;10:825–831.
    1. Severe acute respiratory syndrome (SARS) prevention in Taiwan. Liu HE. J Sch Nurs. 2004;20:76–80.
    1. Severe acute respiratory syndrome: historical, epidemiologic, and clinical features. Hui DSC, Zumla A. Infect Dis Clin North Am. 2019;33:869–889.
    1. From SARS to MERS, thrusting coronaviruses into the spotlight. [Mar;2020 ];Song Z, Xu Y, Bao L, et al. Viruses. 2019 11:0.
    1. Another decade, another coronavirus. Perlman S. N Engl J Med. 2020;382:760–762.
    1. Severe acute respiratory syndrome: report of treatment and outcome after a major outbreak. Sung JJ, Wu A, Joynt GM, et al. Thorax. 2004;59:414–420.
    1. Lessons from the severe acute respiratory syndrome outbreak in Hong Kong. Abdullah AS, Tomlinson B, Cockram CS, Thomas GN. Emerg Infect Dis. 2003;9:1042–1045.

Source: PubMed

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

3
Abonnieren